S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASONE AS INDUCTION THERAPY IN HIGH-RISK TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-04

• C. Touzeau,
• A. Perrrot,
• C. Hulin,
• S. Manier,
• M. Macro,
• M.-L. Chretien,
• L. Karlin,
• O. Decaux,
• C. Jacquet,
• M. Tiab,
• X. Leleu,
• L. Planchce,
• H. Avet-Loiseau,
• P. Moreau

Affiliations

C. Touzeau

1 CHU Nantes - Hotel Dieu, CHU Nantes - Hotel Dieu, Nantes

A. Perrrot

2 Hematology, IUCT Oncopole, Toulouse

C. Hulin

3 Hematology, CHU Bordeaux, Bordeaux

S. Manier

4 Hematology, CHU Lille, Lille

M. Macro

5 Hematology, CHU Caen, Caen

M.-L. Chretien

6 Hematology, CHU Dijon, DIjon

L. Karlin

7 Hematology, CHU Lyon, Lyon

O. Decaux

8 Hematology, CHu Rennes, Rennes

C. Jacquet

9 Hematology, CHU Nancy, Nancy

M. Tiab

10 Hematology, CHD, La Roche sur Yon

X. Leleu

11 Hematology, CHU Poitiers, Poitiers

L. Planchce

12 Biostatistic

H. Avet-Loiseau

2 Hematology, IUCT Oncopole, Toulouse

P. Moreau

13 Hematology, CHU Nantes, Nantes, France